Fenofibrate, a classical PPAR-α agonist, has been reported to prevent cardiac fibrosis in an animal model of type 1 diabetes (T1D), accompanied by enhanced autophagic activity in vivo (Zhang et al., 2016). Here, PPARA is linked to type 1 diabetes mellitus.